Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex)

Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, Berenson JR Abstract Oprozomib (OPZ or ONYX 0912) is an irreversible, orally administered proteasome inhibitor (PI) and an analog of carfilzomib. We set out to determine the anti-angiogenic effect of OPZ using the choriollantoic membrane/feather bud (CAM/FB) model and its anti-MM effects using […]

Outcomes of Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide and Carfilzomib

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR Abstract New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma […]

Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients

Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez, Kyle Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R Berenson Abstract B-cell maturation antigen is expressed on plasma cells. In this study, we have identified serum B-call maturation antigen as […]

TRAF6 Is Over-Expressed in Multiple Myeloma and Blocking Its Intracellular Signaling Shows Both Anti-Tumor and Anti-Bone Resorptive Effects

Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR. Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase (IKK) to regulate the NF-κB and JNK […]

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Berenson J, Manges R, Badarinath S, Cartmell A, McIntyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, Rifkin R Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-h infusion), […]


CHAMPION-1: a phase 1/2 study of weekly carfilzomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma Running title (max 50 characters including spaces): Weekly carfilzomib and dexamethasone for RRMM James R. Berenson,1 Alan Cartmell,2 Alberto Bessudo,3 Roger M. Lyons,4 Wael Harb,5 Dimitrios Tzachanis,6 Richy Agajanian,7 Ralph Boccia,8 Morton Coleman,9 Robert A. Moss,10 Robert […]

Biology of Human Tumors

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S.Wang, Haiming Chen, and James R. Berenson Abstract Purpose: Reduced uninvolved immunoglobulin (Ig) levels are a hallmark of multiple myeloma. We previously showed that Bcell maturation […]

Advances in the Management of Multiple Myeloma

James R Berenson, MD,abc Tanya M Spektor, PhD,c and James Wang, MDab aInstitute for Myeloma and Bone Cancer Research; bJames R Berenson, MD, Inc; and cOncotherapeutics, West Hollywood, California Correspondence: James R Berenson, MD; Disclosures: Dr Berenson is a consultant for and receives honoraria and research funding from Takeda, Amgen, Jansen, Celgene, and Bristol-Meyers-Squibb. […]

Risk of Skin Cancer in Multiple Myeloma Patients

a retrospective cohort study Austin A. Robinson1, James Wang2, Suzie Vardanyan3, Erik K. Madden4, Frank Hebroni4, Kyle A. Udd2, Tanya M. Spektor5, Jason D. Nosrati3, Alex Z. Kitto3, Michael Zahab3, Simrin Cheema6, Darron H. Fors4, Adam Norberg4, Joseph Diehl4, Gabriel N. Waterman7, Regina A. Swift2, John Crowley8, James R. Berenson2,3,5. 1Yale University School of Medicine, […]